A group of UCL Mental Health Masters students summarise a recent literature review that explores the potential pathways to ADHD remission.
[read the full story...]ADHD remission: why do some children ‘outgrow’ ADHD whilst others don’t?
1 Response »
Anorexia nervosa: relapse, remission and recovery
Sarah McDonald asks: What happens after treatment? She summarises a recent systematic review of relapse, remission, and recovery in anorexia nervosa.
[read the full story...]Outcomes in first episode manic psychosis
Matthew Broome writes his debut Mental Elf blog on a three-year clinical and functional outcome comparison between first episode manic psychosis and first-episode schizophrenia.
[read the full story...]CBT versus psychodynamic psychotherapy for social anxiety disorder: long live the dodo or time for a change in research emphasis?
Andrew Shepherd appraises a study of the long-term outcomes of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder, which finds both therapies are efficacious in treating social anxiety disorder in the short- and long-term.
[read the full story...]And if we do nothing? A new systematic review explores natural PTSD remission rates
Who naturally recovers from PTSD and why? A recent meta-regression analysis finds an overall natural remission rate for PTSD of 44%, with no increase in remission after longer observation periods.
[read the full story...]Cochrane review finds ‘solid’ evidence for CBT for anxiety in young people, but lacks evidence for long-term benefits
Anxiety disorders, such as generalised anxiety disorder (GAD), social anxiety, panic disorder and phobias, are common and affect between 5 – 19% of all children and adolescents (Costello, 2004; as cited in James et al, 2013, pg. 6). Anxiety problems in childhood or adolescence can disrupt social and educational life, and may persist into adulthood. [read the full story…]
Escitalopram provides cost-effective remission from depression, according to new meta-analysis
I really enjoyed the discussion in the Guardian over the weekend about poor quality trials and pharmaceutical industry techniques that overhype their drugs in an attempt to shift units. Ben Goldacre’s new Bad Pharma book is well worth a read. New reviews about antidepressants come thick and fast and it’s often hard to know what [read the full story…]